<DOC>
	<DOCNO>NCT02204397</DOCNO>
	<brief_summary>A proof-of-concept safety preliminary clinical efficacy combine regimen INGAP-P β-cell regeneration ustekinumab IL-12-23 autoimmune modulation patient establish T1DM .</brief_summary>
	<brief_title>Study Tolerability Safety Adding Ustekinumab INGAP Peptide 12 Weeks Adult Patients With TD1 Melitis</brief_title>
	<detailed_description>The primary objective study assess safety tolerability 12 week subcutaneous ( SC ) daily administration INGAP-P ( 600 mg SC day three separate injection site ) ustekinumab ( two single injection 45 mg SC , one pretreatment two week INGAP-P treatment begin second one 2 week INGAP-P treatment ) adult patient establish type 1 diabetes mellitus ( T1DM ) . Safety evaluate assess local tolerability , record incidence hypoglycemia , perform safety laboratory measure frequent interval , follow subject closely adverse event ( AEs ) . Secondary objective study generate preliminary data efficacy INGAP-P ustekinumab adult patient establish T1DM , specifically change baseline Week 12 : 1 ) Maximal C-peptide ( Cmax ) mix meal test ( MMT ) glucagon stimulate test ( GST ) ; 2 ) C-peptide release ( AUC ) MMT GST ; 3 ) Fasting C-peptide ; 4 ) Fasting glucose ( breakfast least 8 hour fast ) ; 5 ) Longer term glycemic control reflect glycosylated hemoglobin ( HbA1c ) 1,5-anhydroglucitol ( 1,5-AG ) ; , 6 ) Total daily insulin dose relative body weight .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>1 . Male female patient age 19 40 year old , inclusive , history T1DM &gt; 2 year ≤20 year ; 2 . Female patient breastfeed study within least seven day study complete ; 3 . Receiving multiple daily insulin injection insulin pump therapy &gt; 2 year ; 4 . Body mass index ( BMI ) ≤32 kg/m2 total body weight &lt; 100 kg ; 5 . HbA1c ≤8.2 % , 6 . Fasting Cpeptide level &gt; 0.1 ng/mL &lt; 1.0 ng/mL ; 7 . CBC platelet count must within normal limit , specifically , total absolute neutrophil count must &lt; 1500/μL ; 8 . Willing sign study inform consent document ; 9 . In good general health infection , active tuberculosis ( TB ) , late severe complication , concomitant medical condition would influence outcome trial , discretion Investigator Sponsor ; 10 . If treat angiotensinconverting enzymes/angiotensin II receptor blocker ( ACE/ARB ) , dos unchanged month prior enrollment ; 11 . Females child bear potential must negative urine pregnancy test Day 0 prior dispense drug additionally fulfill one follow criterion : Willing use oral , implantable , transdermal , injectable contraceptive 21 day prior first dose 28 day last dose ; , Willing use another reliable mean contraception approve Investigator ( intrauterine device , female condom , diaphragm spermicide , cervical cap , use condom sexual partner , sterile sexual partner ) Screening last blood sample ( Week 16 ) . 1 . Total daily insulin dosage exceed 1.0 U/kg/day change total daily insulin dose level 50 % ( increase decrease ) within past 3 month ; 2 . Treatment diabetes medication insulin ; 3 . A score 4 restricted response Clarke Hypoglycemia Awareness Survey ; 4 . Systolic diastolic blood pressure &gt; 180 mmHg &gt; 110 mmHg , respectively ; 5 . Clinical worsen retinopathy neuropathy previous 3 month ; 6 . Clinical worsen nephropathy previous 3 month , serum creatinine exceed 2.0 mg/dL , ; 7 . History presence acute chronic pancreatitis , include serum amylase level &gt; 1.5 time upper limit normal ( ULN ) serum lipase level &gt; 2 time ULN ; 8 . Active infection screen study ; 9 . History asthma ; 10 . History TB ; 11 . Administration bacille CalmetteGuérin ( BCG ) vaccine TB one year Screening Visit one year last dose ustekinumab ; 12 . A history presence illness , disease , condition ( include cancer ) could impact patient safety evaluability drug effect , Investigator‟s opinion ; 13 . An episode severe hypoglycemia ( change mental status require assistance ) previous 30 day ; 14 . An episode acute glycemic decompensation associate hyperosmolar nonketotic state diabetic ketoacidosis past 6 month ; 15 . A serum aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin level &gt; 2 time ULN ; 16 . Received investigational product within 30 day admission study prior exist exposure INGAPP , glucagonlike peptide ( GLP1 , GLP2 , analog ) , ustekinumab , TNF block agent ( Patients participate placebo group previous INGAPP study E201 exclude study . ) ; 17 . Known hypersensitivity INGAPP excipient use formulation ; 18 . Known hypersensitivity ustekinumab component product ; 19 . Concurrent plan participation clinical study conduct study ; 20 . Positive urine test cocaine , opiates , amphetamine , cannabinoids ; 21 . Inability fill maintain daily diary screening period prior dose ; 22 . Human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C seropositivity blood sample take screening .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 1 Diabetes mellitus</keyword>
	<keyword>INGAP</keyword>
	<keyword>Ustekinumab</keyword>
</DOC>